UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **DEX-0259**

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

CO	ИРО	SITI	IONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS	
d in	vente	ed by	у:	
	n et a			
			ATION APPLICATION, check appropriate box and supply the requisite information:	
	Conti		tion Divisional Continuation-in-part (CIP) of prior application No.:	
) (h is a Conti	inuat	tion Divisional Continuation-in-part (CIP) of prior application No.:	
	h is a: C onti		tion Divisional Continuation-in-part (CIP) of prior application No.:	
nclo	sed a	are:		
	, .		Application Elements	
1.	\boxtimes	Filir	ng fee as calculated and transmitted as described below	
2.	X	Spe	ecification having pages and including the following:	
	a.	X	Descriptive Title of the Invention	
	b.	X	Cross References to Related Applications (if applicable)	
	C.		Statement Regarding Federally-sponsored Research/Development (if applicable)	
	d.		Reference to Microfiche Appendix (if applicable)	
	e.	X	Background of the Invention	
	f.	X	Brief Summary of the Invention	
	g.		Brief Description of the Drawings (if drawings filed)	
	h.	X	Detailed Description	
	i.	X	Claim(s) as Classified Below	

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0259

Total Pages in this Submission

Application Elements (Continued)										
3.		Drav	wing(s) (when neces	sary as prescribed by 35 USC 113)						
	a.		Formal	Number of Sheets						
	b.		Informal	Number of Sheets						
4.	X	Oath or Declaration								
	a.		☐ Newly executed (original or copy)							
	b.		☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)							
	C.	☑ With Power of Attorney ☐ Without Power of Attorney								
	d.	☐ <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).								
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.								
6.		Computer Program in Microfiche (Appendix)								
7.	X	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)								
	a.	☑ Paper Copy								
	b.	☑ Computer Readable Copy (identical to computer copy)								
	C.	. 🗵 Statement Verifying Identical Paper and Computer Readable Copy								
Accompanying Application Parts										
8.		Assignment Papers (cover sheet & document(s))								
9.		37 CFR 3.73(B) Statement (when there is an assignee)								
10.		English Translation Document (if applicable)								
11.		Information Disclosure Statement/PTO-1449 Copies of IDS Citations								
12.		Preliminary Amendment								
13.	X	Acknowledgment postcard								
14.	X	Certificate of Mailing								
			First Class 🗵 E	xpress Mail (Specify Label No.): EL8	559835041US					

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

was unintentional.

Docket No. DEX-0259

Total Pages in this Submission

	Accompanying Application Parts (Continued)
15.	Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.	Additional Enclosures (please identify below):
	Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
17.	Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.
	Warning
	An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **DEX-0259**

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED								
For	#Filed	#Allowed	#Extra		Rate	Fee		
Total Claims	19	- 20 =	0	x	\$18.00	\$0.00		
ndep. Claims	2	- 3 =	0	х	\$84.00	\$0.00		
Multiple Dependent C	laims (check	if applicable)	×			\$280.00		
					BASIC FEE	\$740.00		
OTHER FEE (specify	v purpose)					\$0.00		
					TOTAL FILING FEE	\$1,020.00		
 ☑ Charge the amount of \$1,020.00 as filing fee. ☑ Credit any overpayment. ☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b). 								
Dated: November 1, 2	001		Li 66	cata & T East Ma	A. Tyrrell, Registration No. Syrrell P.C. ain Street	38,350		
oc:					N.J. 08053 110-1515			

Fax: 856-810-1454

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No. EL859835041US Date of Deposit: November 1, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R 1.10 on the date indicated above and is addressed to the "BOX SEQUENCE", Assistant Commissioner for Patents, Washington, D.C. 20231.

- 1) Patent Application Transmittal Letter (2 copies);
- 2) Application consisting of 153 pages of Specification, including three (3) pages of Claims and one (1) page of Abstract;
- 3) Return Postcard;
- 4) Authorization to charge deposit account \$1,020.00;
- 5) Unexecuted Declaration and Power of Attorney;
- 6) Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825;
- 7) Sequence listing; and
- 8) Diskette containing computer readable copy of Sequence Listing.

Jathlus A. Walf KATHLEEN A. TYRRELL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0259

Inventors: Sun et al.

Serial No.: Not yet assigned

Filing Date: Herewith

Examiner: Not yet assigned

Group Art Unit: Not yet assigned

Title: Compositions and Methods Relating to

Prostate Specific Genes and Proteins

"Express Mail" Label No. EL859835041US Date of Deposit - November 1, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for

Patents, Washington, D.C., 20231

Typéd Name: Kathleen A. Tyrrell, Registration No.38,350

BOX SEQUENCE

Assistant Commissioner for Patents Washington, DC 20231

Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

- (XX) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.

- () I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

Kathleen A. Tyrrell

Registration No. 38,350

Date: November 1, 2001

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053

(856) 810-1515